What are the recommended first‑line and subsequent treatment options for chronic inflammatory demyelinating polyneuropathy (CIDP)?

CIDP Treatment

For chronic inflammatory demyelinating polyneuropathy (CIDP), start with intravenous immunoglobulin (IVIg), corticosteroids, or plasma exchange as first-line therapy, with IVIg being the preferred initial choice for most patients. 1, 2, 3

First-Line Treatment Options

The three established first-line therapies for CIDP are equally effective for induction treatment, but differ in their practical applications:

Intravenous Immunoglobulin (IVIg) - Preferred Initial Choice

• Dosing: 2 g/kg divided over 2-5 days (typically 0.4 g/kg/day for 5 days)
• Advantages: Fastest onset of action, favorable safety profile, no immunosuppression
• Best for: Patients requiring rapid improvement, those with contraindications to steroids, elderly patients, or those with comorbidities
• IVIg works for both induction and maintenance therapy 1, 4, 2

Corticosteroids

• Dosing options:
  • Oral prednisone: 0.5-1 mg/kg/day (typically 60-80 mg daily), then taper
  • IV methylprednisolone pulse: 1 g daily for 3-5 days
• Advantages: Cost-effective, can serve as both induction and maintenance therapy
• Disadvantages: Significant long-term side effects (weight gain, diabetes, osteoporosis, hypertension)
• Best for: Patients without contraindications to steroids who need cost-effective long-term therapy 1, 2, 3

Plasma Exchange (PLEX)

• Dosing: 5-10 sessions performed every other day
• Advantages: Effective when other treatments fail or are contraindicated
• Disadvantages: Requires central line access, risk of line-related thrombosis and bleeding, volume shifts
• Best for: Severe presentations, patients with contraindications to IVIg and steroids, or those not responding to initial therapy 1, 2, 3

Treatment Strategy Algorithm

Initial approach:

1. Start with IVIg as first choice unless specific contraindications exist
2. If IVIg unavailable or contraindicated → use corticosteroids
3. If both IVIg and corticosteroids contraindicated → use plasma exchange
4. For severe presentations with rapid progression → consider combination therapy (corticosteroids + IVIg or corticosteroids + PLEX) from the start 2, 3

Evaluate response at 2-4 weeks:

• If improvement occurs → continue current therapy and plan maintenance strategy
• If no improvement → switch to alternative first-line agent or add second agent
• If partial improvement → consider adding second first-line agent 2, 3

Maintenance Therapy

After achieving initial response, maintenance therapy is typically required:

• IVIg maintenance: Repeat infusions every 3-4 weeks (dose and interval individualized based on response)
• Subcutaneous immunoglobulin (SCIg): Alternative to IVIg for maintenance only, not for induction 4, 2
• Oral corticosteroids: Gradual taper to lowest effective dose
• Combination therapy: May use corticosteroids as steroid-sparing agent with IVIg 3, 5

Second-Line Therapies

If first-line treatments are insufficient, ineffective, or not tolerated:

• Immunosuppressants: Azathioprine, mycophenolate mofetil, methotrexate (used as steroid-sparing agents)
• Rituximab: For refractory cases
• Novel biologics: Monoclonal antibodies targeting neonatal Fc receptors, complement, or CD19/20 (emerging therapies) 2, 5

These should be considered when:

• Inadequate response to first-line therapy after 3-6 months
• Unacceptable side effects from first-line agents
• Need for steroid-sparing strategy
• Frequent relapses requiring high-dose maintenance therapy 3, 5

Critical Monitoring Points

Reassess diagnosis if:

• No response to two different first-line therapies
• Progressive deterioration despite treatment
• Atypical features develop

CIDP misdiagnosis is common—lack of treatment response should prompt reconsideration of the diagnosis rather than automatic escalation to more aggressive therapy 6, 7

Monitor treatment response using:

• Muscle strength testing (MRC scale)
• Functional disability scales
• Nerve conduction studies (at baseline and 6-12 months)
• Quality of life measures 4, 3

Treatment Withdrawal Considerations

Attempt gradual treatment reduction after sustained remission (typically 12+ months of stability), but recognize that many patients require long-term maintenance therapy. Relapse rates are high with treatment discontinuation, so close monitoring during tapering is essential 3, 6